

Anne E Kiltie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1056939/publications.pdf>

Version: 2024-02-01

71
papers

4,528
citations

147801

31
h-index

102487

66
g-index

76
all docs

76
docs citations

76
times ranked

6542
citing authors

#	ARTICLE	IF	CITATIONS
1	Trimodal Therapy. , 2021, , 257-280.		0
2	SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells. Cell Death and Disease, 2021, 12, 165.	6.3	8
3	Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1472-1482.	0.8	8
4	p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiation. Cell Reports, 2021, 35, 109153.	6.4	24
5	Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and Microbubbles. Ultrasound in Medicine and Biology, 2021, 47, 1596-1615.	1.5	4
6	The role of dietary supplements, including biotics, glutamine, polyunsaturated fatty acids and polyphenols, in reducing gastrointestinal side effects in patients undergoing pelvic radiotherapy: A systematic review and meta-analysis. Clinical and Translational Radiation Oncology, 2021, 29, 11-19.	1.7	6
7	Irradiation at Ultra-High (FLASH) Dose Rates Reduces Acute Normal Tissue Toxicity in the Mouse Gastrointestinal System. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1250-1261.	0.8	53
8	Immunofluorescence microscopy-based detection of ssDNA foci by BrdU in mammalian cells. STAR Protocols, 2021, 2, 100978.	1.2	6
9	The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability. Cell Reports, 2021, 37, 110080.	6.4	22
10	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€”An International Collaborative Multistakeholder Effortâ€”. European Urology, 2020, 77, 223-250.	1.9	132
11	Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation. BMC Biology, 2020, 18, 102.	3.8	31
12	Greater utility of molecular subtype rather than epithelialâ€”mesenchymal transition (<sc>EMT</sc>) markers for prognosis in high-risk non-muscle-invasive (<sc>HG1</sc>) bladder cancer. Journal of Pathology: Clinical Research, 2020, 6, 238-251.	3.0	9
13	The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumorsâ€”In Vivo. International Journal of Radiation Oncology Biology Physics, 2020, 107, 212-221.	0.8	22
14	MRE11A Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation. Bladder Cancer, 2019, 5, 147-157.	0.4	2
15	The p97â€”Ataxin 3 complex regulates homeostasis of the <sc>DNA</sc> damage response E3 ubiquitin ligase <sc>RNF</sc> 8. EMBO Journal, 2019, 38, e102361.	7.8	38
16	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 809-818.	0.8	23
17	Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes. European Urology Oncology, 2019, 2, 239-247.	5.4	6
18	Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Surgery, 2019, 154, 184.	4.3	1

#	ARTICLE	IF	CITATIONS
19	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 423-431.	1.6	16
20	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 213-218.	1.9	13
21	Radiosensitization <i>In Vivo</i> by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 381-392.	4.1	31
22	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 413-422.	1.6	32
23	Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer. <i>British Journal of Cancer</i> , 2018, 119, 220-229.	6.4	10
24	The Impact of Histological Variants of Urothelial Carcinoma on Clinical Outcomes Following Trimodality Bladder-sparing Chemoradiation. <i>European Urology</i> , 2017, 72, 61-63.	1.9	3
25	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>European Urology</i> , 2017, 72, 354-365.	1.9	195
26	E3 Ligase cIAP2 Mediates Downregulation of MRE11 and Radiosensitization in Response to HDAC Inhibition in Bladder Cancer. <i>Cancer Research</i> , 2017, 77, 3027-3039.	0.9	41
27	Crowdsourcing for translational research: analysis of biomarker expression using cancer microarrays. <i>British Journal of Cancer</i> , 2017, 116, 237-245.	6.4	16
28	No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy. <i>British Journal of Cancer</i> , 2017, 117, 322-325.	6.4	6
29	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016, 25, 1203-1214.	2.9	38
30	Exploring multidisciplinary practice patterns in the management of muscle invasive bladder cancer (MIBC) across the U.S. and Canada in 2015.. <i>Journal of Clinical Oncology</i> , 2016, 34, 368-368.	1.6	1
31	High-throughput DNA Sequencing Identifies Novel CtIP (RBBP8) Variants in Muscle-invasive Bladder Cancer Patients. <i>Bladder Cancer</i> , 2015, 1, 31-44.	0.4	2
32	Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. <i>Annals of Oncology</i> , 2014, 25, 877-883.	1.2	41
33	Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5435-5445.	7.0	19
34	Re: Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 597-598.	1.9	1
35	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
36	Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours. <i>Oncotarget</i> , 2014, 5, 993-1003.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. <i>Radiotherapy and Oncology</i> , 2013, 108, 429-433.	0.6	37
38	Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination. <i>Cancer Research</i> , 2013, 73, 1611-1620.	0.9	30
39	The emerging role of histone deacetylase (<sc>HDAC</sc>) inhibitors in urological cancers. <i>BJU International</i> , 2013, 111, 537-542.	2.5	35
40	The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. <i>Carcinogenesis</i> , 2012, 33, 581-586.	2.8	103
41	Using Gene Polymorphisms to Assess Bladder Cancer Risk: Progress and Challenges. <i>Journal of Urology</i> , 2012, 187, 379-380.	0.4	1
42	Functional assays to determine the significance of two common XPC 3'UTR variants found in bladder cancer patients. <i>BMC Medical Genetics</i> , 2011, 12, 84.	2.1	3
43	Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 733-738.	1.6	155
44	In vitro functional effects of XPC gene rare variants from bladder cancer patients. <i>Carcinogenesis</i> , 2011, 32, 516-521.	2.8	10
45	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. <i>Human Molecular Genetics</i> , 2011, 20, 4268-4281.	2.9	134
46	A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2010, 42, 415-419.	21.4	169
47	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 978-984.	21.4	493
48	MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2010, 70, 7017-7026.	0.9	184
49	Common predisposition alleles for moderately common cancers: bladder cancer. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 218-224.	3.3	15
50	Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 203-213.	4.1	95
51	Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 6857-6864.	0.9	107
52	Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 310-321.	2.8	19
53	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009, 41, 221-227.	21.4	572
54	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2009, 41, 991-995.	21.4	321

#	ARTICLE	IF	CITATIONS
55	Molecular Epidemiology of DNA Repair Genes in Bladder Cancer. <i>Methods in Molecular Biology</i> , 2009, 472, 281-306.	0.9	10
56	Cancer Biomarkers Associated with Damage Response Genes. , 2009, , 307-330.		0
57	Analysis of variants in DNA damage signalling genes in bladder cancer. <i>BMC Medical Genetics</i> , 2008, 9, 69.	2.1	38
58	Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at United Kingdom Specialist Treatment Center. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 456-463.	0.8	121
59	Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2008, 40, 1307-1312.	21.4	377
60	DNA repair gene XRCC1 polymorphisms and bladder cancer risk. <i>BMC Genetics</i> , 2007, 8, 13.	2.7	34
61	Comprehensive Analysis of 22 XPC Polymorphisms and Bladder Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2537-2541.	2.5	40
62	APE1 and XRCC1 Protein Expression Levels Predict Cancer-Specific Survival Following Radical Radiotherapy in Bladder Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 6205-6211.	7.0	79
63	DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining. <i>Nucleic Acids Research</i> , 2004, 32, 5249-5259.	14.5	107
64	Double strand break repair by non-homologous end joining in bladder cancer. <i>European Urology Supplements</i> , 2003, 2, 90.	0.1	0
65	Development of a rapid, small-scale DNA repair assay for use on clinical samples. <i>Nucleic Acids Research</i> , 2003, 31, 83e-83.	14.5	38
66	Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer. <i>Radiotherapy and Oncology</i> , 2000, 55, 179-186.	0.6	114
67	Training to treat cancer: future developments. <i>British Journal of Hospital Medicine</i> , 1999, 60, 519-521.	0.2	4
68	Lack of correlation between residual radiation-induced DNA damage, in keratinocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 481-487.	0.8	16
69	A correlation between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. <i>Radiotherapy and Oncology</i> , 1999, 51, 55-65.	0.6	55
70	A correlation between residual DNA double-strand breaks and clonogenic measurements of radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 1137-1144.	0.8	36
71	Survival and quality of life of paediatric intracranial germ cell tumour patients treated at the Christie Hospital, 1972-1993. <i>Medical and Pediatric Oncology</i> , 1995, 25, 450-456.	1.0	48